SlideShare a Scribd company logo
1 of 41
Hypolipidemic Agents Sachin Kuchya,  MD Assistant Professor, Department of Pharmacology NSCB Medical College, Jabalpur
Why do we need them? ,[object Object],[object Object],[object Object]
Overview of Presentation  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
GLOSSARY ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
PHYSIOLOGY Enterohepatic circulation  - Bile acids CHL Pool Dietary CHL  De novo CHL synthesis HMG CoA reductase enz. VLDL Chylomicrons 50%  50%  VLDL LDL TG  CHL ,[object Object],[object Object],[object Object],[object Object],To various body tissues,  Gut  HDL2  HDL3  CHL ester TG  LDL CETP Tightly regulated  Diurnal variation
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Non Pharmacological & Pharmacological targets 1 2 3 4 5 6 7 Dietary Atheroma HDL2  CHL Pool CHL  VLDL Chylomicrons 50%  50%  VLDL LDL TG  CHL Gut  HDL3  CHL ester TG  LDL CETP Bile acids
Statins – effect on lipids ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Statins – additional effects ,[object Object],[object Object],[object Object],[object Object]
Statins – Clinical Pharmacokinetics ,[object Object],[object Object],[object Object],[object Object],[object Object]
Statins – adverse effects  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Statins – indications ,[object Object],[object Object]
Bile acid binding resins ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Bile acid binding resins – adverse effects ,[object Object],[object Object],[object Object],[object Object],[object Object]
Bile acid binding resins ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Ezetimibe ,[object Object],[object Object],[object Object],[object Object]
Ezetimibe  ,[object Object],[object Object],[object Object]
Niacin  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Physiologic dose, as vitamin B3– 50mg/ day Pharmacologic dose, as hypolipidemic agent –  2 – 6gm/day.
Niacin ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Niacin - indications ,[object Object],[object Object],[object Object]
Fibric acid derivatives ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Fibric acid derivatives ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Fibric acid  - indications ,[object Object],[object Object],[object Object]
CETP inhibitor - Torcetrapib ,[object Object],[object Object]
ω3 – fatty acids ,[object Object],[object Object],[object Object],[object Object],[object Object]
Clinical states  ,[object Object],[object Object]
Chylomicronemia  Dietary restriction  1 Clinical state - 1 CHL Pool Dietary CHL  VLDL Chylomicrons 50%  50%  VLDL LDL TG  CHL To various body tissues,  Gut  HDL2  HDL3  CHL ester TG  LDL CETP 1 Bile acids
Hypercholesterolemia 2 5 4 3 Cholesterol absorption inhibitor Bile acid binding resin HMG CoA reductase inhibitor VLDL secretion inhibitor Clinical state - 2 CHL Pool Dietary CHL  De novo CHL synthesis HMG CoA reductase enz. VLDL Chylomicrons 50%  50%  VLDL LDL TG  CHL To various body tissues,  Gut  HDL2  HDL3  CHL ester TG  LDL CETP 2 5 3 4 Bile acids
CHL Pool Dietary CHL  VLDL Chylomicrons 50%  50%  VLDL LDL TG  CHL atheroma Gut  HDL2  HDL3  CHL ester TG  LDL CETP 6 5 Hypertriglyceridemia  6 5 VLDL secretion inhibitor Fibric acid derivatives Clinical state - 3
Low HDL-c levels VLDL secretion inhibitor CETP inhibitor 5 7 Clinical state - 4 CHL Pool Dietary CHL  VLDL Chylomicrons 50%  50%  VLDL LDL TG  CHL Atheroma  Gut  HDL2  HDL3  CHL ester TG  LDL CETP 7 5
Special Population ,[object Object],[object Object]
Special population – Children ,[object Object],[object Object],[object Object],[object Object]
Special population – Children ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Women ,[object Object],[object Object],[object Object]
Combination regimens – why? ,[object Object],[object Object],[object Object],[object Object]
Combination regimens – when? ,[object Object],[object Object],[object Object]
LDL-c reduction ,[object Object],[object Object],[object Object]
VLDL reduction ,[object Object],[object Object]
Minimize doses and side effects ,[object Object]
Diabetic patient ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Diabetic patient - drugs ,[object Object],[object Object],[object Object],[object Object],[object Object]
Thank you  Topic is open for queries

More Related Content

What's hot (20)

Angina and Antianginal drugs
Angina and Antianginal drugsAngina and Antianginal drugs
Angina and Antianginal drugs
 
Pharmacology of Hypolipidaemics drugs
Pharmacology of Hypolipidaemics drugsPharmacology of Hypolipidaemics drugs
Pharmacology of Hypolipidaemics drugs
 
Statins
StatinsStatins
Statins
 
Statins
StatinsStatins
Statins
 
Hypolipidemic drugs
Hypolipidemic drugsHypolipidemic drugs
Hypolipidemic drugs
 
Antilipemics
AntilipemicsAntilipemics
Antilipemics
 
Anti diabetic drugs
Anti diabetic drugsAnti diabetic drugs
Anti diabetic drugs
 
Hypolipidaemic drugs
Hypolipidaemic drugsHypolipidaemic drugs
Hypolipidaemic drugs
 
Drug therapy of hypercholesterolaemia
Drug therapy of hypercholesterolaemia Drug therapy of hypercholesterolaemia
Drug therapy of hypercholesterolaemia
 
Angiotensin receptor blockers
Angiotensin receptor blockersAngiotensin receptor blockers
Angiotensin receptor blockers
 
Oral hypoglycemic agents
Oral hypoglycemic agentsOral hypoglycemic agents
Oral hypoglycemic agents
 
ARB in the management of Hypertension
ARB in the management of HypertensionARB in the management of Hypertension
ARB in the management of Hypertension
 
Antianginal drugs (VK)
Antianginal drugs (VK)Antianginal drugs (VK)
Antianginal drugs (VK)
 
HYPOLIPIDEMIC DRUGS
HYPOLIPIDEMIC DRUGSHYPOLIPIDEMIC DRUGS
HYPOLIPIDEMIC DRUGS
 
Antihyperlipidemia
AntihyperlipidemiaAntihyperlipidemia
Antihyperlipidemia
 
Gliclazide MR in the management of Type 2 Diabetes Mellitus
Gliclazide MR in the management of Type 2 Diabetes MellitusGliclazide MR in the management of Type 2 Diabetes Mellitus
Gliclazide MR in the management of Type 2 Diabetes Mellitus
 
Vildagliptin in the management of Type 2 Diabetes mellitus
Vildagliptin in the management of Type 2 Diabetes mellitusVildagliptin in the management of Type 2 Diabetes mellitus
Vildagliptin in the management of Type 2 Diabetes mellitus
 
Potassium sparing diuretics
Potassium sparing diureticsPotassium sparing diuretics
Potassium sparing diuretics
 
Hydrochlorthiazide
HydrochlorthiazideHydrochlorthiazide
Hydrochlorthiazide
 
Antihyperlipidemic drug
Antihyperlipidemic drugAntihyperlipidemic drug
Antihyperlipidemic drug
 

Similar to Hypolipidemic agents

Powerpoints Hypolipidemics
Powerpoints HypolipidemicsPowerpoints Hypolipidemics
Powerpoints HypolipidemicsMD Specialclass
 
Powerpoints Hypolipidemics
Powerpoints HypolipidemicsPowerpoints Hypolipidemics
Powerpoints HypolipidemicsMD Specialclass
 
Management of Hyperlipidemia
Management of HyperlipidemiaManagement of Hyperlipidemia
Management of HyperlipidemiaHealth Forager
 
Hypolipidemic drugs Dr. Kiran Piparva.pptx
Hypolipidemic drugs Dr. Kiran Piparva.pptxHypolipidemic drugs Dr. Kiran Piparva.pptx
Hypolipidemic drugs Dr. Kiran Piparva.pptxKiran Piparva
 
Hypolipidemic drugs
Hypolipidemic drugsHypolipidemic drugs
Hypolipidemic drugsajaykumarbp
 
Antihyperlipidemics2
Antihyperlipidemics2Antihyperlipidemics2
Antihyperlipidemics2Dr Shah Murad
 
Antihyperlipidemics1
Antihyperlipidemics1Antihyperlipidemics1
Antihyperlipidemics1Dr Shah Murad
 
Antihyperlipidimic drug therapy-current and noval approaches.pptx
Antihyperlipidimic drug therapy-current and noval approaches.pptxAntihyperlipidimic drug therapy-current and noval approaches.pptx
Antihyperlipidimic drug therapy-current and noval approaches.pptxMohammedObaidMohiudd
 
Hypolipidaemic Drugs
Hypolipidaemic DrugsHypolipidaemic Drugs
Hypolipidaemic DrugsDinesh Kumar
 
Lipid Guidelines - Dr. Ajay Kantharia
Lipid Guidelines - Dr. Ajay KanthariaLipid Guidelines - Dr. Ajay Kantharia
Lipid Guidelines - Dr. Ajay KanthariaIndian Health Journal
 
Class hypolipidemics
Class hypolipidemics Class hypolipidemics
Class hypolipidemics Raghu Prasada
 
NurseReview.Org - Antilipemics Updates (medical pharmacology)
NurseReview.Org - Antilipemics Updates (medical pharmacology)NurseReview.Org - Antilipemics Updates (medical pharmacology)
NurseReview.Org - Antilipemics Updates (medical pharmacology)jben501
 

Similar to Hypolipidemic agents (20)

Powerpoints Hypolipidemics
Powerpoints HypolipidemicsPowerpoints Hypolipidemics
Powerpoints Hypolipidemics
 
Powerpoints Hypolipidemics
Powerpoints HypolipidemicsPowerpoints Hypolipidemics
Powerpoints Hypolipidemics
 
Management of Hyperlipidemia
Management of HyperlipidemiaManagement of Hyperlipidemia
Management of Hyperlipidemia
 
hyperlipidemic drugs..pptx
hyperlipidemic drugs..pptxhyperlipidemic drugs..pptx
hyperlipidemic drugs..pptx
 
Dyslipidemia approach
Dyslipidemia approachDyslipidemia approach
Dyslipidemia approach
 
Hypolipidemic drugs Dr. Kiran Piparva.pptx
Hypolipidemic drugs Dr. Kiran Piparva.pptxHypolipidemic drugs Dr. Kiran Piparva.pptx
Hypolipidemic drugs Dr. Kiran Piparva.pptx
 
Lipid modifying drug dr. tariqul
Lipid modifying drug  dr. tariqulLipid modifying drug  dr. tariqul
Lipid modifying drug dr. tariqul
 
Hypolipidemic drugs
Hypolipidemic drugsHypolipidemic drugs
Hypolipidemic drugs
 
Antihyperlipidemics2
Antihyperlipidemics2Antihyperlipidemics2
Antihyperlipidemics2
 
Antihyperlipidemics1
Antihyperlipidemics1Antihyperlipidemics1
Antihyperlipidemics1
 
Antihyperlipidimic drug therapy-current and noval approaches.pptx
Antihyperlipidimic drug therapy-current and noval approaches.pptxAntihyperlipidimic drug therapy-current and noval approaches.pptx
Antihyperlipidimic drug therapy-current and noval approaches.pptx
 
Anti dyslipidemic agents
Anti dyslipidemic agentsAnti dyslipidemic agents
Anti dyslipidemic agents
 
Hyperlipidemia
Hyperlipidemia Hyperlipidemia
Hyperlipidemia
 
Hypolipidaemic Drugs
Hypolipidaemic DrugsHypolipidaemic Drugs
Hypolipidaemic Drugs
 
Hyperlipidemia
HyperlipidemiaHyperlipidemia
Hyperlipidemia
 
Lipid Guidelines - Dr. Ajay Kantharia
Lipid Guidelines - Dr. Ajay KanthariaLipid Guidelines - Dr. Ajay Kantharia
Lipid Guidelines - Dr. Ajay Kantharia
 
Class hypolipidemics
Class hypolipidemics Class hypolipidemics
Class hypolipidemics
 
NurseReview.Org - Antilipemics Updates (medical pharmacology)
NurseReview.Org - Antilipemics Updates (medical pharmacology)NurseReview.Org - Antilipemics Updates (medical pharmacology)
NurseReview.Org - Antilipemics Updates (medical pharmacology)
 
Dyslipidemia
DyslipidemiaDyslipidemia
Dyslipidemia
 
Hyperlipidemia
HyperlipidemiaHyperlipidemia
Hyperlipidemia
 

Hypolipidemic agents

  • 1. Hypolipidemic Agents Sachin Kuchya, MD Assistant Professor, Department of Pharmacology NSCB Medical College, Jabalpur
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22.
  • 23.
  • 24.
  • 25.
  • 26. Chylomicronemia Dietary restriction 1 Clinical state - 1 CHL Pool Dietary CHL VLDL Chylomicrons 50% 50% VLDL LDL TG CHL To various body tissues, Gut HDL2 HDL3 CHL ester TG LDL CETP 1 Bile acids
  • 27. Hypercholesterolemia 2 5 4 3 Cholesterol absorption inhibitor Bile acid binding resin HMG CoA reductase inhibitor VLDL secretion inhibitor Clinical state - 2 CHL Pool Dietary CHL De novo CHL synthesis HMG CoA reductase enz. VLDL Chylomicrons 50% 50% VLDL LDL TG CHL To various body tissues, Gut HDL2 HDL3 CHL ester TG LDL CETP 2 5 3 4 Bile acids
  • 28. CHL Pool Dietary CHL VLDL Chylomicrons 50% 50% VLDL LDL TG CHL atheroma Gut HDL2 HDL3 CHL ester TG LDL CETP 6 5 Hypertriglyceridemia 6 5 VLDL secretion inhibitor Fibric acid derivatives Clinical state - 3
  • 29. Low HDL-c levels VLDL secretion inhibitor CETP inhibitor 5 7 Clinical state - 4 CHL Pool Dietary CHL VLDL Chylomicrons 50% 50% VLDL LDL TG CHL Atheroma Gut HDL2 HDL3 CHL ester TG LDL CETP 7 5
  • 30.
  • 31.
  • 32.
  • 33.
  • 34.
  • 35.
  • 36.
  • 37.
  • 38.
  • 39.
  • 40.
  • 41. Thank you Topic is open for queries